Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00403494 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease
A Phase 2 study of Intermittent Claudication, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- Phase 2
- Development phase
- 190
- Enrollment target
- 20
- Study locations
NCT00403494 is a Phase 2 study of Intermittent Claudication that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 190 participants, roughly in line with the 199-participant average among 11 other Intermittent Claudication trials with a reported enrollment target. The trial reports 20 study locations across 12 states.
The verdict
NCT00403494, a Phase 2 study of Intermittent Claudication, has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 190 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate whether sapropterin dihydrochloride is safe and effective in the treatment of intermittent claudication (IC) caused by peripheral arterial disease (PAD).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Sapropterin Dihydrochloride
Study Locations (20)
California
- - Sacramento
- - San Diego
- - Santa Ana
- - Santa Rosa
Other
- - Buenos Aires
- - Corrientes
- - Santa Fe
Florida
- - Clearwater
- - Jacksonville
Texas
- - Dallas
- - San Antonio
Virginia
- - Norfolk
- - Richmond
Arizona
- - Scottsdale
Georgia
- - Conyers
Indiana
- - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00403494
The ClinicalTrials.gov registry entry for NCT00403494 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 199-participant average among 11 other Intermittent Claudication trials with a reported enrollment target. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Intermittent Claudication appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00403494 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT00403494 about?
NCT00403494 is a clinical study titled "A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease". The purpose of this study is to evaluate whether sapropterin dihydrochloride is safe and effective in the treatment of intermittent claudication (IC) caused by peripheral arterial disease (PAD).
What is the current status of trial NCT00403494?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 2006-12. Estimated completion is 2009-01.
What conditions does trial NCT00403494 study?
This clinical trial studies the following conditions: Intermittent Claudication.
What interventions are being tested in trial NCT00403494?
The interventions under investigation include: Placebo (OTHER), Sapropterin Dihydrochloride (DRUG).
Who is sponsoring clinical trial NCT00403494?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00403494 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intermittent Claudication
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Response to Exercise and Nitric Oxide in PAD
RECRUITING · Phase 2
-
Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease
COMPLETED · Phase 2
-
Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication
COMPLETED · Phase 2
-
Improving Mobility After Revascularization in Peripheral Artery Disease
RECRUITING · Phase 3
-
MetfOrmin BenefIts Lower Extremities With Intermittent Claudication
RECRUITING · Phase 3
-
The Chocolate Touch Study
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.